1-(3-甲基-4-吡啶)哌嗪 | 112940-51-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 中文名称: 1-(3-甲基-4-吡啶)哌嗪
• 英文名称: 1-(3-methylpyridin-4-yl)piperazine
• 英文别名: 1-(3-methyl-4-pyridinyl)piperazine；1-(3-methylpyrid-4-yl)piperazine
• CAS: 112940-51-9
• 化学式: C₁₀H₁₅N₃
• 分子量: 177.249
• InChiKey: QIELQJJSSZTEJW-UHFFFAOYSA-N

物化性质

• 沸点：
  328.6±37.0 °C(Predicted)
• 密度：
  1.059±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.7
• 重原子数：
  13
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  28.2
• 氢给体数：
  1
• 氢受体数：
  3

安全信息

• 海关编码：
  2933990090

反应信息

• 作为反应物：
  描述：

  1-(3-甲基-4-吡啶)哌嗪 在 potassium carbonate 、 一水合肼 作用下， 以 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 9.0h， 生成 3-[4-(3-Methyl-pyridin-4-yl)-piperazin-1-yl]-propylamine
  参考文献：
  名称：

  N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α₁-Adrenoceptor Antagonists

  摘要：

  Novel arylpiperazines were identified as alpha(1)-adrenoceptor(BR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides,;as well as carboxamides of quinoline, I,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta;a were used as a ''negative screen'' for the test antagonists. Binding to alpha(1)-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g, 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the alpha(1)-AR subtype prevalent in the human lower urinary tract (pA(2) values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the alpha(1D)-AR.

  DOI：

  10.1021/jm970166j
• 作为产物：
  描述：

  4-氯-3-甲基吡啶 在 sodium hydroxide 作用下， 以 甲醇 为溶剂， 反应 21.5h， 生成 1-(3-甲基-4-吡啶)哌嗪
  参考文献：
  名称：

  N-Arylpiperazinyl-N‘-propylamino Derivatives of Heteroaryl Amides as Functional Uroselective α₁-Adrenoceptor Antagonists

  摘要：

  Novel arylpiperazines were identified as alpha(1)-adrenoceptor(BR) subtype-selective antagonists by functional in vitro screening. 3-[4-(ortho-Substituted phenyl)piperazin-1-yl]propylamines were derivatized with N,N-dimethyl anthranilamides, nicotinamides,;as well as carboxamides of quinoline, I,8-naphthyridine, pyrazolo[3,4-b]pyridine, isoxazolo[3,4-b]pyridine, imidazo[4,5-b]pyridine, and pyrazolo[1,5-a]pyrimidines. Strips of rabbit bladder neck were employed as a predictive assay for antagonism in the human lower tract. Rings of rat aorta;a were used as a ''negative screen'' for the test antagonists. Binding to alpha(1)-ARs was relatively sensitive to size and electronic features of the arylpiperazine portion of the antagonists and permissive to these features on the heteroaryl carboxamide side. These structure-affinity findings were exploited to produce nicotinamides (e.g, 13ii and 25x) and pyrazolo[3,4-b]pyridines (e.g. 37f and 37y) ligands with nanomolar affinity at the alpha(1)-AR subtype prevalent in the human lower urinary tract (pA(2) values: 8.8, 10.7, 9.3, and 9.9, respectively) and displaying 2-3 orders of magnitude selectivity over the alpha(1D)-AR.

  DOI：

  10.1021/jm970166j

文献信息

• Piperazinyl-substituted pyridine and imidazole anti-arrhythmic agents
  申请人：Pfizer, Inc.

  公开号：US04806536A1

  公开（公告）日：1989-02-21

  A series of novel 4-substituted piperazinyl-pyridine and 4-substituted piperazinyl-imidazole compounds have been prepared, including their pharmaceutically acceptable salts, wherein the 4-substituent is a lower phenylalkyl group or a derivative thereof further substituted on the phenyl moiety by a sulphamoyl or sulphonylamino group or by a nitro, amino or acetamido group. These particular compounds are useful in therapy as highly effective anti-arrhythmic agents and therefore, are of value in the treatment of various cardiac arrythmias. The most preferred member compound of the series is N-4-[1-hydroxy-2-(4-[4-pyridinyl]-1-piperazinyl)ethyl]phenyl} methanesulphonamide. Methods for preparing all these compounds from known starting materials are provided.

  一系列新颖的4-取代哌嗪基吡啶和4-取代哌嗪基咪唑化合物已经制备完成，包括它们的药用可接受盐，其中4-取代基是一个较低的苯基烷基或其衍生物，进一步在苯基上被磺酰胺基或磺酰胺氨基团或硝基、氨基或乙酰氨基团取代。这些特定化合物在治疗中具有高效的抗心律失常作用，因此在治疗各种心律失常方面具有价值。该系列中最优选的成员化合物是N-4-[1-羟基-2-(4-[4-吡啶基]-1-哌嗪基)乙基]苯基}甲磺酰胺。提供了从已知起始材料制备所有这些化合物的方法。
• [EN] AMINOPYRIMIDINONES AS INTERLEUKIN RECEPTOR-ASSOCIATED KINASE INHIBITORS<br/>[FR] AMINOPYRIMIDINONES EN TANT QU'INHIBITEURS DE KINASES ASSOCIÉES AU RÉCEPTEUR DE L'INTERLEUKINE
  申请人：MERCK SHARP & DOHME

  公开号：WO2013066729A1

  公开（公告）日：2013-05-10

  This invention relates to aminopyrimidinone compounds of Formula (I) that are inhibitors of Interleukin receptor-associated kinases, in particular IRAK-4, and are useful in the treatment or prevention of inflammatory diseases, including rheumatoid arthritis and inflammatory bowel disease.

  这项发明涉及一种式（I）的氨基嘧啶酮化合物，它们是白细胞介素受体相关激酶的抑制剂，特别是IRAK-4，并且在治疗或预防炎症性疾病，包括类风湿关节炎和炎症性肠病方面是有用的。
• Novel Nucleic Acid Binding Small Molecules Discovered Using DNA-Encoded Chemistry
  作者：Alexander Litovchick、Xia Tian、Michael I. Monteiro、Kaitlyn M. Kennedy、Marie-Aude Guié、Paolo Centrella、Ying Zhang、Matthew A. Clark、Anthony D. Keefe

  DOI：10.3390/molecules24102026

  日期：——

  affinity-mediated selection against this target demonstrated high-affinity binding and high specificity over DNA sequences not containing G-quartet motifs. These compounds demonstrated a moderate ability to discriminate between different G-quartet motifs and also demonstrated activity in a cell-based assay, suggesting direct target engagement in the cell. DNA-encoded chemical libraries and affinity-mediated

  受到许多报道的 DNA 编码化学库在具有蛋白质靶标的药物发现项目中的成功应用的启发，我们决定将此平台应用于核酸靶标。我们使用了 33 个不同的 DNA 编码化学文库和亲和介导选择的 1200 亿化合物组来发现一组 DNA 靶标的结合物。在这里，我们报告成功发现了与 DNA G 四重体特异性相互作用的小分子，这些小分子是在基因组 DNA 的富含 G 的区域（包括癌基因的启动子区域）中发现的稳定结构基序。在这项研究中，我们选择了在 c-myc 启动子中发现的 G-四重奏序列作为主要目标。使用针对该目标的亲和介导选择富集的化合物表现出对不含 G-四重体基序的 DNA 序列的高亲和力结合和高特异性。这些化合物表现出区分不同 G-四重体基序的中等能力，并且在基于细胞的测定中也表现出活性，表明细胞中的直接靶标参与。DNA 编码的化学文库和亲和介导的选择特别适合发现与在细胞环境之外没有固有活性的靶标的结
• [EN] PIPERIDIN-4-YLPIPERAZINE COMPOUNDS FOR THE TREATMENT OF HCV INFECTION<br/>[FR] COMPOSÉS DE PIPÉRIDIN-4-YLPIPÉRAZINE POUR LE TRAITEMENT D'UNE INFECTION À VHC
  申请人：GENOSCIENCE PHARMA

  公开号：WO2010081851A1

  公开（公告）日：2010-07-22

  The invention relates to new piperazine-pieridine compounds having anti-viral activity and particularly anti-HCV activity. The invention further relates to pharmaceutical compositions comprising compounds according to the invention.

  该发明涉及具有抗病毒活性，特别是抗丙型肝炎病毒活性的新哌嗪-哌啶化合物。该发明还涉及包含根据该发明的化合物的药物组合物。
• Phenyl piperazine anti-arrhythmia agents
  申请人：Pfizer Inc.

  公开号：US04788196A1

  公开（公告）日：1988-11-29

  A series of pyridyl or imidazolyl substituted phenyl piperazines having utility as anti-arrhythmic agents is disclosed.

  揭示了一系列具有抗心律失常作用的吡啶基或咪唑基取代的苯基哌嗪类化合物。